N6-methyladenosine modification and skin diseases.
10.11817/j.issn.1672-7347.2025.240222
- Author:
Ling JIANG
1
,
2
;
Yibo HU
3
;
Jing CHEN
1
,
4
Author Information
1. Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha
2. 798878752@qq.com.
3. Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
4. 43700351@qq.com.
- Publication Type:Review
- Keywords:
N 6-methyladenosine;
drug development;
epigenetics;
inflammatory and immune-related skin diseases;
skin tumors
- MeSH:
Humans;
Skin Neoplasms/metabolism*;
Skin Diseases/metabolism*;
Adenosine/genetics*;
Psoriasis/genetics*;
Carcinoma, Squamous Cell/genetics*;
Carcinoma, Basal Cell/genetics*;
Melanoma/genetics*
- From:
Journal of Central South University(Medical Sciences)
2025;50(3):382-395
- CountryChina
- Language:English
-
Abstract:
Currently, research on N6-methyladenine (m6A) is extensive in the field of oncology, while studies involving m6A and skin diseases remain relatively limited. Based on existing reports, we searched PubMed and Web of Science for literature related to m6A and dermatological conditions. Analysis of citation counts and journal impact factors revealed a significant upward trend in the volume of m6A-related research. Term frequency analysis of titles and abstracts indicated that studies mainly focus on skin tumors and inflammatory or immune-related skin diseases, particularly melanoma, psoriasis, and skin development. Transcriptomic data from the Gene Expression Omnibus (GEO) were analyzed, revealing differential expression of m6A-related genes in 4 types of skin tumors (including squamous cell carcinoma and basal cell carcinoma) as well as in inflammatory skin diseases such as psoriasis and atopic dermatitis, and potential mechanisms of action were also explored. Findings suggest that m6A modifications exhibit heterogeneity between neoplastic and non-neoplastic skin diseases. However, the regulatory mechanisms of m6A dynamic modifications on key genes involved in dermatological disorders remain unclear and warrant further investigation.
